Perspective Therapeutics (NYSE:CATX) Rating Lowered to Neutral at Bank of America

Perspective Therapeutics (NYSE:CATX - Get Free Report) was downgraded by research analysts at Bank of America from a "buy" rating to a "neutral" rating in a research note issued to investors on Monday, Marketbeat.com reports. They currently have a $5.00 price target on the stock, down from their previous price target of $24.00. Bank of America's target price points to a potential upside of 37.74% from the company's current price.

Several other brokerages also recently commented on CATX. Royal Bank of Canada reduced their target price on Perspective Therapeutics from $29.00 to $27.00 and set an "outperform" rating for the company in a research note on Friday, August 16th. UBS Group initiated coverage on shares of Perspective Therapeutics in a report on Thursday, October 24th. They set a "buy" rating and a $20.00 target price for the company. Cantor Fitzgerald reissued an "overweight" rating on shares of Perspective Therapeutics in a report on Monday, September 9th. Oppenheimer decreased their target price on shares of Perspective Therapeutics from $22.00 to $16.00 and set an "outperform" rating on the stock in a research report on Friday. Finally, Wedbush reaffirmed an "outperform" rating and set a $11.00 price objective (down previously from $20.00) on shares of Perspective Therapeutics in a research report on Thursday. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $15.14.

Perspective Therapeutics Stock Up 4.6 %

Shares of NYSE CATX traded up $0.16 during midday trading on Monday, reaching $3.63. The company's stock had a trading volume of 4,188,756 shares, compared to its average volume of 811,385. Perspective Therapeutics has a fifty-two week low of $2.28 and a fifty-two week high of $19.05. The stock has a 50 day simple moving average of $11.52.

Perspective Therapeutics (NYSE:CATX - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.21). The company had revenue of $0.37 million for the quarter. Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. As a group, sell-side analysts expect that Perspective Therapeutics will post -0.86 EPS for the current year.

Institutional Investors Weigh In On Perspective Therapeutics

Hedge funds have recently modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of Perspective Therapeutics by 34.6% during the first quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company's stock valued at $21,158,000 after acquiring an additional 4,566,356 shares during the last quarter. Janus Henderson Group PLC acquired a new position in shares of Perspective Therapeutics in the 1st quarter worth approximately $15,511,000. Virtu Financial LLC bought a new stake in Perspective Therapeutics during the first quarter valued at $138,000. Bank of New York Mellon Corp grew its stake in Perspective Therapeutics by 214.0% during the second quarter. Bank of New York Mellon Corp now owns 137,268 shares of the company's stock worth $1,369,000 after purchasing an additional 93,548 shares during the period. Finally, Rhumbline Advisers bought a new position in shares of Perspective Therapeutics during the 2nd quarter worth approximately $630,000. Institutional investors and hedge funds own 54.66% of the company's stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.